Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$13.82M-15.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Barber
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 147
- Beta
- 1.47
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.46
Financials
Revenue
$13.82M-15.9%Net Income
$-22.86MEBITDA
$-18.77M-1198.6%Free Cash Flow
$-9.65M-396.9%EPS (diluted)
$-0.18Shares Outstanding (diluted)
124.99M+525.0%Operating Expenses
$18.02MCash & Debt
$98.49MReturn of Capital
$0.00Revenue by Segment (annual)
$45.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.55M | $-83.78M | $-0.76 |
| 2024 | $57.56M | $-44.14M | $-0.51 |
| 2023 | $50.58M | $-7.87M | $-0.13 |
| 2022 | $47.68M | $-54.41M | $-1.12 |
| 2021 | $50.83M | $-70.54M | $-1.85 |
| 2020 | $45.85M | $-55.78M | $-1.66 |
| 2019 | $52.61M | $-66.25M | $-2.87 |
| 2018 | $67.43M | $-61.38M | $-2.96 |
| 2017 | $66.92M | $-8.94M | $-0.45 |
| 2016 | $51.78M | $-9.60M | $-0.39 |
Valuation
AQSThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·7d ago·Neutral
… biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company's Board of Directors, effective October 14, 2026.
View source ↗ - Newsglobenewswire.com·19d ago·Negative
…he applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm™ (dibutepinephr…
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Negative
Aquestive Therapeutics Q2 Earnings Call Highlights Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Administration.
View source ↗ - Newszacks.com·55d ago·Negative
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2026, and provided a strategic business update.
View source ↗ - Newsbenzinga.com·56d ago·Negative
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.10 per share
Typical surprise -35.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.18 vs $-0.10miss
- Wed, May 13$-0.07 vs $-0.14beat
- Wed, Mar 4$-0.26 vs $-0.13miss
- Wed, Nov 5$-0.14 vs $-0.11miss
- Mon, Aug 11$-0.14 vs $-0.18beat
- Mon, May 12$-0.24 vs $-0.17miss
Estimates and results for AQST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AQST officers and directors.
- Bought
- —
- Sold
- $4.0m
0 trades
23 trades
- Barber Danielsold
- Korczynski Sherrysold
- Barber Danielsold
- Barber Danielsold
- Barber Danielsold
- Krop Juliesold
- Barber Danielsold
- Barber Danielsold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AQST.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.